DLBCL Treatment

Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let's have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be...

In recent years, the field of oncology has witnessed a remarkable transformation thanks to the groundbreaking innovation of antibody-drug conjugates (ADCs). These game-changing molecules have three key components: an antibody drug, a potent cytotoxic payload, and a specialized linker protein that binds them togethe...

The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for patients with DLBCL.  Recently, off-the-shelf bispecific antibodies have grow...

CAR T-cell therapy is a type of immunotherapy that uses your body's white blood cells to fight your lymphoma. It uses a particular kind of white blood cell known as T lymphocytes or T cells. An essential part of CART therapies is lymphodepleting conditioning, which is administered to the patient before infusion of ...